Company intelligence / Profile preview

Respirogen

Boulder, Colorado, United Statesinnosphereventures.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Respirogen has developed a lipid-based oxygen microbubble technology designed for systemic oxygen delivery independent of lung function. Preclinical data demonstrated that OMBs could keep rats alive indefinitely despite severely compromised lungs. As of late 2021, the company was preparing for first-in-human clinical trials.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Oxygen microbubbles (OMB)enhanced oxygen compositions
Industry: Biotech

Drug pipeline

1 asset

Respirogen Micro-Oxygen

Beyond the preview

Go deeper on Respirogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respirogen.

Explore the full profile